Shenzhen Hepalink Pharmaceutical Co. Ltd. | Ownership
Companies that own Shenzhen Hepalink Pharmaceutical Co. Ltd.
Golden Eagle Asset Management Co., Ltd.
10,285,741
0.83%
10,285,741
0.76%
09/30/2017
Yunnan International Trust Co., Ltd.
7,101,248
0.56%
7,101,248
0.65%
09/30/2017
Hunan Trust Co., Ltd.
6,699,516
0.54%
6,699,516
7.56%
09/30/2017
Guotai Asset Management Co., Ltd.
1,696,860
0.14%
-391,199
0.07%
12/31/2017
Changsheng Fund Management Co., Ltd.
822,622
0.07%
0
0.12%
12/31/2017
China Southern Asset Management Co., Ltd.
661,540
0.05%
-2,380,180
0.02%
12/31/2017
China Asset Management Co., Ltd.
505,644
0.04%
-110,800
0.01%
12/31/2017
The Vanguard Group, Inc.
489,180
0.04%
0
0%
07/31/2018
E Fund Management Co., Ltd.
287,168
0.02%
-107,800
0.01%
12/31/2017
GF Fund Management Co., Ltd.
254,546
0.02%
-307,487
0.01%
12/31/2017
| Address |
No. 21 Langshan Road
Shenzhen Guangdong 518057
China
|
|
Employees
|
- |
| Website |
http://www.hepalink.com |
| Updated |
07/08/2019 |
| Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is engaged in the research, production and distribution of heparin sodium bulk drugs. It offers heparin sodium products, including Food and Drug Administration (FDA) grade heparin sodium ingredients and ordinary grade heparin sodium ingredients. The company was founded by Li Tan, Li Li and Shan Yu on April 21, 1998 and is headquartered in Shenzhen, China. |
